Abiopharma

🔍 ROTHBLATT MARTINE A (Executive)

Company: UNITED THERAPEUTICS Corp (UTHR)

Report Date: 2026-07-30

Detailed Transactions and Holdings:

• Acquired 9,500 shares of Common Stock at $135.42 per share (Direct)
  Date: 2026-07-30 | Code: M | equity_swap_involved: false | shares_owned_after: 333,943.00 | transaction_form_type: 4 | Footnotes: F1, F2
• Sold 644 shares of Common Stock at $523.0381 per share (Direct)
  Date: 2026-07-30 | Code: S | equity_swap_involved: false | shares_owned_after: 333,299.00 | transaction_form_type: 4 | Footnotes: F1, F3, F2
• Sold 1,486 shares of Common Stock at $523.8749 per share (Direct)
  Date: 2026-07-30 | Code: S | equity_swap_involved: false | shares_owned_after: 331,813.00 | transaction_form_type: 4 | Footnotes: F1, F4, F2
• Sold 4,846 shares of Common Stock at $524.8842 per share (Direct)
  Date: 2026-07-30 | Code: S | equity_swap_involved: false | shares_owned_after: 326,967.00 | transaction_form_type: 4 | Footnotes: F1, F5, F2
• Sold 2,084 shares of Common Stock at $525.798 per share (Direct)
  Date: 2026-07-30 | Code: S | equity_swap_involved: false | shares_owned_after: 324,883.00 | transaction_form_type: 4 | Footnotes: F1, F6, F2
• Sold 400 shares of Common Stock at $526.923 per share (Direct)
  Date: 2026-07-30 | Code: S | equity_swap_involved: false | shares_owned_after: 324,483.00 | transaction_form_type: 4 | Footnotes: F1, F7, F2
• Sold 40 shares of Common Stock at $528.96 per share (Direct)
  Date: 2026-07-30 | Code: S | equity_swap_involved: false | shares_owned_after: 324,443.00 | transaction_form_type: 4 | Footnotes: F1, F2
• Holds 0 shares of Common Stock (Direct)
  Date: 2026-07-30 | Code: H | shares_owned_after: 40,513.00
• Holds 0 shares of Common Stock (Direct)
  Date: 2026-07-30 | Code: H | nature_of_ownership: by Spouse | shares_owned_after: 166.00
• Holds 0 shares of Common Stock (Direct)
  Date: 2026-07-30 | Code: H | nature_of_ownership: by Trust | shares_owned_after: 249,108.00 | Footnotes: F8
• Holds 0 shares of Common Stock (Direct)
  Date: 2026-07-30 | Code: H | nature_of_ownership: by Trust | shares_owned_after: 45,596.00 | Footnotes: F9
• Holds 0 shares of Common Stock (Direct)
  Date: 2026-07-30 | Code: H | nature_of_ownership: by Trust | shares_owned_after: 8,902.00 | Footnotes: F10
• Sold 9,500 shares of Stock Option at $135.42 per share (Derivative)
  Date: 2026-07-30 | Code: M | Expires: 2027-03-15 | Exercise: 2023-03-15 | equity_swap_involved: false | shares_owned_after: 236,910.00 | transaction_form_type: 4 | Footnotes: F1, F11

Footnotes:

• F1: This exercise of stock options and sale of the resulting shares of common stock was pursuant to a pre-arranged 10b5-1 trading plan adopted by the reporting person on November 7, 2025. This plan will continue until the earlier of: (a) the exercise of 1,734,410 stock options, all of which expire on March 15, 2027; or (b) December 31, 2026.
• F10: Shares held in family trusts as to which the Reporting Person is sole trustee and sole beneficiary or co-trustee and settlor with power to revoke.
• F11: Stock options held in a family trust as to which the Reporting Person shares investment power and the Reporting Person and immediate family members are beneficiaries.
• F2: Shares held in family trusts as to which the Reporting Person shares investment power and the Reporting Person and/or immediate family members are beneficiaries.
• F3: This transaction was executed in multiple trades at prices ranging from $522.43 to $523.38. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
• F4: This transaction was executed in multiple trades at prices ranging from $523.43 to $524.41. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
• F5: This transaction was executed in multiple trades at prices ranging from $524.43 to $525.41. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
• F6: This transaction was executed in multiple trades at prices ranging from $525.43 to $526.30. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
• F7: This transaction was executed in multiple trades at prices ranging from $526.50 to $527.45. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
• F8: Shares held in family trusts as to which the Reporting Person's spouse is sole trustee and sole beneficiary or co-trustee and settlor with power to revoke.
• F9: Shares held in family trusts as to which the Reporting Person's spouse shares investment power and the Reporting Person and/or immediate family members are beneficiaries.